HRGN (Harvard Apparatus Regenerative Technology) Research & Development: $2.87 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HRGN Harvard Apparatus Regenerative Technology Inc HRGN
14 GF Score
Price $1.40
! 2 Warning Signs
View Full Analysis

What is Harvard Apparatus Regenerative Technology Research & Development?

Harvard Apparatus Regenerative Technology HRGN 14 Research & Development is $2.87 Mil as of Jun. 2026. GuruFocus rates HRGN with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Harvard Apparatus Regenerative Technology's Research & Development for the three months ended in Jun. 2026 was $0.95 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was $2.87 Mil.

Harvard Apparatus Regenerative Technology  (OTCPK:HRGN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Harvard Apparatus Regenerative Technology Research & Development Related Terms

Harvard Apparatus Regenerative Technology Research & Development Historical Data

* Premium members only.

The historical data trend for Harvard Apparatus Regenerative Technology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Apparatus Regenerative Technology Research & Development Chart

Harvard Apparatus Regenerative Technology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.59 1.74 3.06 2.31 2.65

Harvard Apparatus Regenerative Technology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.66 0.70 0.56 0.95
HRGN
14GF Score
Harvard Apparatus Regenerative Technology Inc HRGN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harvard Apparatus Regenerative Technology Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $2.87 Mil mean?
Harvard Apparatus Regenerative Technology (HRGN) has a Research & Development of $2.87 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Harvard Apparatus Regenerative Technology and its competitors.
Is Harvard Apparatus Regenerative Technology's Research & Development too high?
Harvard Apparatus Regenerative Technology's current Research & Development is $2.87 Mil. Overall, Harvard Apparatus Regenerative Technology has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Apparatus Regenerative Technology's Research & Development compare to JVA and BRLS?
Harvard Apparatus Regenerative Technology's Research & Development of $2.87 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Consumer Packaged Goods company?
A good Research & Development depends on the Consumer Packaged Goods industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Harvard Apparatus Regenerative Technology and its competitors. Harvard Apparatus Regenerative Technology's current Research & Development is $2.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Apparatus Regenerative Technology stock overvalued right now?
Harvard Apparatus Regenerative Technology (HRGN) has a current Research & Development of $2.87 Mil. The current Research & Development is $2.87 Mil. Harvard Apparatus Regenerative Technology's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Harvard Apparatus Regenerative Technology (HRGN), the current Research & Development is $2.87 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Harvard Apparatus Regenerative Technology Business Description

Address 84 October Hill Road, Suite 11, Holliston, MA, USA, 01746
Harvard Apparatus Regenerative Technology is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastrointestinal system and other organs that result from cancer, trauma, or birth defects. Its technology is based on a proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. The Company has two operating and reportable segments: Regenerative Biotech, focused on the development of regenerative medicine treatments with operations currently in the United States, and Consumer Health Products relating to consumer health products with operations currently in Asia.
14GF Score

Get the complete analysis for HRGN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.40
Price